公开(公告)号：US11273178B2

公开(公告)日：2022-03-15

申请号：US16055241

申请日：2018-08-06

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Rachel Lea Eisenbach ,  Yosi Gozlan ,  Esther Tzehoval

IPC: A61K35/17 ,  C07K14/725 ,  C12N15/10 ,  C12N15/63 ,  C12N15/85 ,  C12N5/0783 ,  C12N5/10 ,  C07K14/705

Abstract: The present invention relates to methods and systems for increasing the affinity of a T cell receptor (TCR) to its ligand by subjecting the TCR gene to somatic hypermutation. The present invention further relates to use of affinity maturated TCRs to create T cells reactive against a selected antigen.

公开(公告)号：US20210030856A1

公开(公告)日：2021-02-04

申请号：US17041974

申请日：2019-03-26

Applicant: Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts ,  Yeda Research and Development Co., LTD.

Inventor： Rachel Lea Eisenbach ,  Esther Tzehoval ,  Gal Cafri ,  Adi Sharbi Yunger ,  Mareike Grees

IPC: A61K39/00 ,  C07K14/74 ,  A61P35/00

Abstract: The present invention pertains to a novel cell based tumor vaccine platform. The invention provides a method for modifying antigen presenting cells (APCs) to present both MHC class I and/or MHC class II peptides in context of improved peptide presentation protein complexes in order to increase activation of a patient's immune response. In this invention, an MHC II mRNA dendritic cell based vaccine platform was developed to activate CD4+T cells in patients and to enhance the anti-tumor response. The invariant chain (Ii) was modified and the semi-peptide CLIP was replaced with an MHCII binding peptide sequences of tumor associated antigens. These chimeric MHC II constructs are presented by APCs and induce proliferation of tumor specific CD4+T cells. The invention provides the constructs, proteins, nucleic acids, recombinant cells, as well as medical applications of these products.

公开(公告)号：US10081663B2

公开(公告)日：2018-09-25

申请号：US13958277

申请日：2013-08-02

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Lea Eisenbach ,  Yosi Gozlan ,  Esther Tzehoval

IPC: C12N15/12 ,  C12N15/63 ,  C12N15/85 ,  C12N5/16 ,  C07K14/705 ,  C07K14/725 ,  C12N15/10 ,  A61K35/17

CPC classification number: C07K14/70503 ,  A61K35/17 ,  C07K14/7051 ,  C12N15/102

Abstract: The present invention relates to methods and systems for increasing the affinity of a T cell receptor (TCR) to its ligand by subjecting the TCR gene to somatic hypermutation. The present invention further relates to use of affinity maturated TCRs to create T cells reactive against a selected antigen.